Management and Distinguished Scientists Will Provide Overview on Company's Diagnostic and Therapeutic Development Programs, as Well as on the microRNA
REHOVOT, Israel and NEW YORK, October 2 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (Nasdaq: ROSG), a global leader in microRNA-based diagnostics and therapeutics, announced today it will host its R&D Day on microRNAs and their significant potential in cancer treatment and other medical applications. This event will take place on Wednesday, October 26, from 12:00 pm-3:00 pm (New York time), and will be webcasted live on the "Investors" section of the company's website at http://www.rosettagenomics.com.
Amir Avniel, Chief Executive Officer of Rosetta Genomics, and Dalia Cohen, Ph.D., Executive Vice President, Global Head of Research & Development, will provide an overview of the company's development and commercialization plans for microRNA-based diagnostics and therapeutics, as well as its Intellectual Property.
In addition, the following leading scientific experts will provide their insights on microRNAs' future role in therapeutics and diagnostics:
Harvey Pass, MD, Professor and Chief, Division of Thoracic Surgery and Thoracic Oncology at NYU Medical Center.
Mahesh Mansukhani, MD, Associate Director of the Molecular Pathology Laboratory at Columbia University Medical Center
Prof. Moshe Hod, Director, Division of Maternal Fetal Medicine, Helen Schneider Hospital for Women, Rabin Medical Center
Eva M Hernando-Monge Ph.D., B.S., Assistant Professor, Department of Pathology, New York University School of Medicine
"As microRNAs are a relatively new field of study, there is significant demand to obtain a broader knowledge of microRNAs and their commercial potential," stated Mr. Avniel. "Our distinguished panel of speakers will give a unique insight into how new technologies are integrated into medical practice and the impact these discoveries have on patient care."
This invitation-only event will be webcasted and posted on the Rosetta Genomics website. To access the live audio webcast for this conference, please log on to the Rosetta Genomics website at http://www.rosettagenomics.com approximately 15 minutes prior to the presentation in order to register and download any necessary software. A replay of the audio presentation will be available following the event.
MicroRNAs (miRNAs) are a recently discovered, naturally occurring form of RNAi. These small RNAs act as protein regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNAs have been shown to have different expression levels in certain diseased versus normal tissues. As a result, these differences potentially provide for a novel diagnostic strategy for many diseases. MicroRNAs are thought to play a key role in the differentiation of cells into specific cell types performing various functions in the body.
About Rosetta Genomics
Rosetta Genomics (Nasdaq: ROSG) is a leader in the development of microRNA-based diagnostics and therapeutics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and strategic alliances with leading biotechnology companies, Rosetta Genomics is working to develop a full range of diagnostic and therapeutic products based on microRNAs. The company's primary focus is in the development of microRNA-based products to diagnose and treat different forms of cancer and other diseases
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the role of miRNAs in human physiology and disease, and the potential of microRNAs in the diagnosis and treatment of disease, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover and develop novel diagnostics products, which is unproven and may never lead to marketable products; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its product candidates, all of which are in early stages of development; Rosetta's ability to obtain regulatory approval for products; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2006 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.
|SOURCE Rosetta Genomics Ltd|
Copyright©2007 PR Newswire.
All rights reserved